Literature DB >> 16998873

Antibody structure, instability, and formulation.

Wei Wang1, Satish Singh, David L Zeng, Kevin King, Sandeep Nema.   

Abstract

The number of therapeutic monoclonal antibody in development has increased tremendously over the last several years and this trend continues. At present there are more than 23 approved antibodies on the US market and an estimated 200 or more are in development. Although antibodies share certain structural similarities, development of commercially viable antibody pharmaceuticals has not been straightforward because of their unique and somewhat unpredictable solution behavior. This article reviews the structure and function of antibodies and the mechanisms of physical and chemical instabilities. Various aspects of formulation development have been examined to identify the critical attributes for the stabilization of antibodies. (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association.

Mesh:

Substances:

Year:  2007        PMID: 16998873     DOI: 10.1002/jps.20727

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  181 in total

1.  Biotherapeutic formulation factors affecting metal leachables from stainless steel studied by design of experiments.

Authors:  Shuxia Zhou; Brad Evans; Christian Schöneich; Satish K Singh
Journal:  AAPS PharmSciTech       Date:  2012-01-13       Impact factor: 3.246

2.  High concentration formulation studies of an IgG2 antibody using small angle X-ray scattering.

Authors:  Charlotte Rode Mosbæk; Petr V Konarev; Dmitri I Svergun; Christian Rischel; Bente Vestergaard
Journal:  Pharm Res       Date:  2012-04-03       Impact factor: 4.200

3.  High-throughput analysis of concentration-dependent antibody self-association.

Authors:  Shantanu V Sule; Muppalla Sukumar; William F Weiss; Anna Marie Marcelino-Cruz; Tyler Sample; Peter M Tessier
Journal:  Biophys J       Date:  2011-10-05       Impact factor: 4.033

4.  Insights into protein-polysorbate interactions analysed by means of isothermal titration and differential scanning calorimetry.

Authors:  Claudia Hoffmann; Alfred Blume; Inge Miller; Patrick Garidel
Journal:  Eur Biophys J       Date:  2009-02-03       Impact factor: 1.733

Review 5.  High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Authors:  Rajoshi Chaudhuri; Yuan Cheng; C Russell Middaugh; David B Volkin
Journal:  AAPS J       Date:  2013-10-31       Impact factor: 4.009

6.  Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies.

Authors:  Santosh V Thakkar; Neha Sahni; Sangeeta B Joshi; Bruce A Kerwin; Feng He; David B Volkin; C Russell Middaugh
Journal:  Protein Sci       Date:  2013-08-19       Impact factor: 6.725

Review 7.  Assessment and significance of protein-protein interactions during development of protein biopharmaceuticals.

Authors:  Sandeep Yadav; Jun Liu; Thomas M Scherer; Yatin Gokarn; Barthélemy Demeule; Sonoko Kanai; James D Andya; Steven J Shire
Journal:  Biophys Rev       Date:  2013-03-14

8.  Temperature stability of proteins: Analysis of irreversible denaturation using isothermal calorimetry.

Authors:  Arne Schön; Benjamin R Clarkson; Maria Jaime; Ernesto Freire
Journal:  Proteins       Date:  2017-08-08

9.  Precipitation of a monoclonal antibody by soluble tungsten.

Authors:  Jared S Bee; Stephanie A Nelson; Erwin Freund; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

Review 10.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.